DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer

Information source: Daxor Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypoalbuminemia; Heart Failure; Nephrosis; Cirrhosis; Shock

Phase: N/A

Status: Completed

Sponsored by: Daxor Corporation

Official(s) and/or principal investigator(s):
Joseph Feldschuh, MD, Principal Investigator, Affiliation: Daxor Corporation


The DAXOR Corporation manufactures and distributes a blood volume analyzer. The analysis is based on the tracer dilution principle utilizing radioiodine labeled human serum albumin. In addition to calculating human blood volume it is hypothesized that measurement of the dilution of the tracer can also yield an accurate measurement of total body albumin.

Clinical Details

Official title: Pilot Research Study to Asses Total Body Albumin Levels

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Total Body Albumin

Detailed description: Twenty adult individuals underwent a standard blood volume measurement. The specimens for this determination are normally collected over a period of approximately 40 minutes. For the determination of total body albumin, additional specimens were collect over a three to four day period until the counts in the blood specimens were stable. Calculation of the degree of dilution over this time interval is thought to represent dilution of the tracer in albumin in both the intra and extravascular space. The ratio of albumin in the intravascular to the extravascular space is available in the medical literature. The total volume in which the tracer is distributed can be determined from the dilution determined. A calculation of total body albumin is therefore possible. Computation of the total body albumin for the test subjects (all normal individuals) was consistent with values for total body albumin in the literature. The purpose of the development of this method is to permit clinicians to determine albumin status in patients with disturbances in albumin such as burn patients, cirrhotic patients, nephrotic patients as well as patients with protein losing gastroenteropathies.


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- Normal adult males and females.

- Females in the childbearing age group to have test to exclude pregnancy

Exclusion Criteria:

- Children,

- pregnant females

Locations and Contacts

Additional Information

Starting date: January 2009
Last updated: March 1, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017